清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract PS2-10-06: Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy

作者
Eric J. Jaehnig,M. Holt,J. Zecha,Matthew S. Glover,W. Kelly,Barrett R. B. Nuttall,Bryant Lee McCue,Ivan Marin,S. Carter,Elizabeth Bonefas,Logan Healy,George E. Miles,M. Anurag,S. Hilsenbeck,B. Zhang,S. Hess,A. M. Thompson
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (4_Supplement): PS2-10
标识
DOI:10.1158/1557-3265.sabcs25-ps2-10-06
摘要

Abstract Background: Breast cancer is a heterogeneous disease, comprising approximately 70% hormone receptor-positive (HR+), 15% HER2-positive (HER2+), and 15% triple-negative breast cancer (TNBC) cases. As standard of care, HR+ tumors are treated with hormone therapy, often after surgery. However, chemotherapy may also be used before surgery (neoadjuvant setting). HER2+ breast cancer responds well (50-70% pathological Complete Response, pCR) to targeted anti-HER2 therapies. In contrast, TNBC is primarily treated with neoadjuvant chemotherapy with only 30-50% achieving pCR. Identifying biomarkers predictive of pCR or that indicate alternative therapeutic strategies can help tailor therapy. Recent studies utilizing proteogenomics data (DNA, RNA, protein, and phosphorylation site profiles from the same tumor) from clinical trials highlighted candidates including LIG1 loss in TNBC and GPRC5A/TPBG overexpression in HER2+ tumors as potential predictive biomarkers and therapeutic targets. This study applies proteogenomic profiling to pre-treatment biopsies from tumors treated with physician-selected neoadjuvant chemotherapy to further explore putative targets for precision oncology. Methods: Microscaled proteogenomic profiling was conducted on 51 treatment-naive primary breast tumor core needle biopsies. Subtyping was determined via IHC: HER2+ (IHC 3+), HER2 Equivocal (IHC 2+), HR+ (ER or PR positive), or TNBC (negative for all three receptors). All received physician-selected neoadjuvant regimens, and pCR was evaluated after surgical resection. Multi-omics profiling of tumor sample from each biopsy included whole-exome sequencing (WES), RNA-seq, and mass spectrometry-based proteomics and phosphoproteomics. Both data-dependent acquisition (DDA) and more sensitive data-independent acquisition (DIA) proteomics were used. Results: Proteomic profiles were obtained for 16 HER2+, 17 HR+, and 18 TNBC patients. WES data were acquired for 50 patients; RNA-seq for 26. DIA quantified more total proteins/sites than DDA, though measurements for top variable genes were highly correlated. To assess the potential for each proteomics data type to inform precision oncology, both were included in all subsequent analyses. The highest pCR rate (69%) was achieved in HER2+ tumors treated with dual antibody therapy where all 4 non-pCR tumors were HR+, a known resistance marker, and 3 were HER2 equivocal with lower HER2 protein expression. Both the DIA and DDA data for GPRC5A protein also confirmed significantly higher expression in non-pCR vs. pCR HER2+ tumors. HR+, HER2- tumors had the lowest pCR (12.5%), but two pCR cases co-treated with pembrolizumab showed high expression of cell cycle and immune proteins. TNBC showed 35% (6/17) pCR overall, improving to 56% (5/9) when treatment included pembrolizumab. Non-pCR tumors had lower cell cycle/immune protein levels and higher epithelial-mesenchymal transition protein levels versus pCR tumors. Detailed proteogenomic profiles for FDA-approved drug targets, TNBC-specific kinases, and cell membrane proteins enriched in the context of non-pCR TNBC cases will be presented. Conclusion: This study demonstrates the feasibility of proteogenomic profiling from clinical breast tumor biopsies and highlights mechanisms of anti-HER2 resistance, potential factors underlying exceptional chemotherapy response in ER+ cancers, and candidate alternative therapeutic targets for non-pCR TNBC, offering a template for future precision oncology efforts. Citation Format: E. Jaehnig, M. Holt, J. Zecha, M. S. Glover, W. Kelly, B. Nuttall, B. McCue, I. Marin, S. Carter, E. Bonefas, L. Healy, G. Miles, M. Anurag, S. Hilsenbeck, B. Zhang, S. Hess, A. Thompson. Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-10-06.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飞飞的应助被武雨寒采纳,获得10
6秒前
美好雁卉完成签到,获得积分10
16秒前
包容的映之完成签到,获得积分10
23秒前
彩色的芷容完成签到 ,获得积分10
23秒前
谦让康完成签到 ,获得积分10
24秒前
朱洪帆完成签到,获得积分20
37秒前
靓丽的伟祺完成签到,获得积分10
49秒前
从容的凡旋完成签到,获得积分10
51秒前
Jun的应助被朱洪帆采纳,获得10
52秒前
无私的碧玉完成签到,获得积分10
56秒前
果酱完成签到,获得积分10
56秒前
万能图书馆的应助被无限幻枫采纳,获得10
57秒前
59秒前
Maestro_S的应助被朱洪帆采纳,获得10
1分钟前
1分钟前
KalEl发布了新的文献求助10
1分钟前
Zhangym完成签到 ,获得积分10
1分钟前
安静的傲松完成签到,获得积分10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
欢喜映阳完成签到,获得积分10
1分钟前
开心恶天完成签到,获得积分10
1分钟前
zjh123完成签到,获得积分10
1分钟前
lily完成签到 ,获得积分10
1分钟前
1分钟前
xuxu213完成签到,获得积分20
1分钟前
1分钟前
无限幻枫发布了新的文献求助10
1分钟前
顺利的三德完成签到,获得积分10
1分钟前
华无剑的应助被xuxu213采纳,获得10
1分钟前
和谐的小懒虫完成签到,获得积分10
1分钟前
李思雨完成签到 ,获得积分10
1分钟前
苗条的之桃完成签到,获得积分10
2分钟前
无辜的凝安完成签到,获得积分10
2分钟前
李成恩完成签到 ,获得积分10
2分钟前
Bill02完成签到 ,获得积分10
2分钟前
外向的香岚完成签到,获得积分10
2分钟前
Xuezhuoxin完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159011
求助须知:如何正确求助?哪些是违规求助? 9554538
关于积分的说明 21719449
捐赠科研通 7748505
什么是DOI,文献DOI怎么找? 3427122
关于科研通互助平台的介绍 2552015
邀请新用户注册赠送积分活动 2471370